₹ 1894.2
Key Takeaways
Risk factor
Low price volatility
Profitability factor
Somewhat favourable analyst view
About
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, North America, Latin America, Europe, and internationally. The company provides branded and generic formulations in the therapeutic areas of dermatology, respiratory, and oncology; and various active pharmaceutical ingredients. Its product pipeline includes ISB 830 (telazorlimab), an OX40 antagonist monoclonal antibody,...
Company Valuation
From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks. Specifically, the stock is fairly valued on P/E, overvalued o
Target Price
The average target price of GLENMARK.NS is 2294 and suggests 21% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to
